A Phase 2/3 study to investigate the efficacy and safety of luveltamab tazevibulin versus IC
chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal
cancers) expressing FOLR1.

This is a randomized, multicenter, international, open-label, 2-part, Phase 2/3 study
designed to assess the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy
in subjects with relapsed platinum-resistant epithelial ovarian cancer expressing FOLR1.

Part 1 will consist of 2 luveltamab tazevibulin dosing cohorts (Cohort A and Cohort B), with
subjects randomized 1:1. Part 1 will be used to select the optimized dosing regimen.

Part 2 will further evaluate the efficacy and safety of the selected dosing regimen versus IC
chemotherapy.

Luveltamab tazevibulin will be administered intravenously (IV) over a 1-hour infusion time
every 3 weeks.

Inclusion Criteria:

1. High grade serous epithelial ovarian cancer, fallopian tube or primary peritoneal
cancer

2. Age ??? 18 years

3. ECOG performance status 0 to 1

4. Positive FOLR1 expression per central laboratory testing

5. Relapsed platinum-resistant epithelial ovarian cancer and received a total of 1 to 3
prior regimens

6. Prior bevacizumab treatment is required, if labeled and available as standard of care
per institutional guidelines, unless subject has documented contraindication

7. At least 1 measurable target lesion per RECIST v1.1

8. Adequate organ function

Exclusion Criteria:

1. Low grade (Grade 1) ovarian carcinoma, clear cell, mucinous, endometrioid,
sarcomatous, and mixed histology ovarian carcinomas

2. Prior treatment with a FOLR1- targeting ADCs or with ADCs that contain a tubulin
inhibitor

3. Primary platinum-refractory disease

4. History of severe allergic or anaphylactic reactions to monoclonal antibody therapy or
to antibody-related fusion protein treatment

5. Pre-existing clinically significant ocular disorders, severe chronic obstructive
pulmonary disease or asthma, clinically significant cardiac or cerebrovascular
disease, or other significant concurrent, uncontrolled medical condition

6. Previous solid organ transplantation

7. History or clinical signs of meningeal or active central nervous system involvement

8. Concurrent participation in another therapeutic treatment trial

If you are interested in participating in this study, call The JamesLine at 800-293-5066 to make an appointment with the principal investigator listed or ask your doctor if you are eligible for this study.